James Doherty

4.9k total citations · 2 hit papers
67 papers, 3.7k citations indexed

About

James Doherty is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, James Doherty has authored 67 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Cellular and Molecular Neuroscience, 32 papers in Molecular Biology and 13 papers in Cognitive Neuroscience. Recurrent topics in James Doherty's work include Neuroscience and Neuropharmacology Research (47 papers), Receptor Mechanisms and Signaling (21 papers) and Tryptophan and brain disorders (10 papers). James Doherty is often cited by papers focused on Neuroscience and Neuropharmacology Research (47 papers), Receptor Mechanisms and Signaling (21 papers) and Tryptophan and brain disorders (10 papers). James Doherty collaborates with scholars based in United States, United Kingdom and China. James Doherty's co-authors include Raymond Dingledine, Stephen Kanes, Steven M. Paul, Yunfei Huang, Michael C. Quirk, Ethan Hoffmann, Shane Raines, Samantha Meltzer‐Brody, Edward P. Christian and Jeffrey M. Jonas and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

James Doherty

67 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Zuranolone vs Placebo in Postpartum Depression

2021 149 citations James Doherty, Sigui Li et al. profile →
Zuranolone for the Treatment of Postpartum Depression

2023 93 citations Robert Lasser, Amy Bullock et al. profile →

Peers

Countries citing papers authored by James Doherty

Since Specialization

Citations

This map shows the geographic impact of James Doherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Doherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Doherty more than expected).

Fields of papers citing papers by James Doherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Doherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Doherty. The network helps show where James Doherty may publish in the future.

Co-authorship network of co-authors of James Doherty

This figure shows the co-authorship network connecting the top 25 collaborators of James Doherty. A scholar is included among the top collaborators of James Doherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Doherty. James Doherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease 2024 ·Clinical and Translational Science ·Aaron Koenig, Michael Lewis, (unknown), Sigui Li, (unknown), Jing Dai, Abdul J. Sankoh, (unknown), James Doherty, (unknown)	9
2	Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study 2023 ·Neuropsychopharmacology ·Sagar V. Parikh, Scott T. Aaronson, Sanjay J. Mathew, Gustavo Alva, Charles DeBattista, Stephen Kanes, Robert Lasser, Amy Bullock, (unknown), JungAh Jung, Fiona Forrestal, (unknown), (unknown), (unknown), James Doherty	15
3	Zuranolone, a Positive Allosteric Modulator of the GABA_A Receptor: Hypothesized Mechanism of Action in Major Depressive Disorder 2023 ·CNS Spectrums ·Stephen M. Stahl, Rebecca Hammond, (unknown), Simon Kyaga, (unknown), Mark H. Pollack, James Doherty	3
4	SAGE-718: A First-in-ClassN-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment 2022 ·Journal of Medicinal Chemistry ·Matthew D. Hill, María‐Jesús Blanco, Francesco G. Salituro, (unknown), Jacob T. Beckley, Michael A. Ackley, Jing Dai, James Doherty, Boyd L. Harrison, Ethan Hoffmann, Tatiana M. Kazdoba, (unknown), Michael Lewis, Michael C. Quirk, Albert J. Robichaud	28
5	24(S)-Hydroxycholesterol Levels are Decreased in Early Huntington’s Disease and Are Associated with Deficits in Several Cognitive Domains (4070) 2020 ·Neurology ·Michael Lewis, Jing Dai, Amrita Mohan, Sarah J. Tabrizi, James Doherty, Albert J. Robichaud, Michael C. Quirk	4
6	Using a Multimodal Biomarker Approach to Identify Functional Target Engagement of the Novel NMDA Positive Allosteric Modulator SAGE-718 (1944) 2020 ·Neurology ·Aaron Koenig, Harald Murck, (unknown), Yingchun Luo, Sigui Li, Brandon J. Farley, David P. Nguyen, (unknown), Michael C. Quirk, Stephen Kanes, James Doherty	1
7	Mechanistic PK/PD Model of Neuroactive Steroid GABAA Positive Allosteric Modulation and Effects on TETRAS Assessment in Essential Tremor (4499) 2020 ·Neurology ·David P. Nguyen, Anne C. Smith, (unknown), E. Hoffman, James Paskavitz, Angela Wehr, (unknown), Amy Bullock, Abdul J. Sankoh, Albert J. Robichaud, Stephen Kanes, James Doherty, Michael C. Quirk	1
8	Metabotropic, but not allosteric, effects of neurosteroids on GABAergic inhibition depend on the phosphorylation of GABAA receptors 2019 ·Journal of Biological Chemistry ·(unknown), Yihui Zhang, Amit Modgil, (unknown), Thuy N. Vien, Michael A. Ackley, James Doherty, Paul Davies, Stephen J. Moss	44
9	Brexanolone as adjunctive therapy in super‐refractory status epilepticus 2017 ·Annals of Neurology ·Eric S. Rosenthal, Jan Claassen, Mark S. Wainwright, Aatif M. Husain, Henrikas Vaitkevicius, Shane Raines, Ethan Hoffmann, Helen Colquhoun, James Doherty, Stephen Kanes	78
10	Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models 2017 ·Epilepsy Research ·Rebecca Hammond, Alison L. Althaus, Michael A. Ackley, Carla Maciag, (unknown), Francesco G. Salituro, Albert J. Robichaud, James Doherty	19
11	The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model 2017 ·Scientific Reports ·Nicole A. Hawkins, Michael Lewis, Rebecca Hammond, James Doherty, Jennifer A. Kearney	24
12	Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats 2016 ·Psychopharmacology ·(unknown), Manoranjan S. D’Souza, (unknown), James Doherty, A.J. Cross, Athina Markou	19
13	AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study 2016 ·Schizophrenia Research ·Robert E. Litman, Mark A. Smith, James Doherty, A.J. Cross, Shane Raines, Lev Gertsik, Stephen R. Zukin	66
14	Rescue of deficient amygdala tonic γ‐aminobutyric acidergic currents in theFmr^–/ymouse model of fragile X syndrome by a novel γ‐aminobutyric acid type A receptor‐positive allosteric modulator 2015 ·Journal of Neuroscience Research ·Brandon S. Martin, Gabriel Martínez-Botella, Carlos M. Loya, Francesco G. Salituro, Albert J. Robichaud, Molly M. Huntsman, (unknown), James Doherty, Jackie D. Corbin	8
15	Different oxysterols have opposing actions at N-methyl-d-aspartate receptors 2014 ·Neuropharmacology ·(unknown), Amanda Taylor, (unknown), James Doherty, Kathiresan Krishnan, Douglas F. Covey, Steven M. Paul, Charles F. Zorumski, Steven Mennerick	75
16	The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator ofN-Methyl-d-Aspartate Receptors 2013 ·Journal of Neuroscience ·Steven M. Paul, James Doherty, Albert J. Robichaud, Gabriel M. Belfort, Brian Y. Chow, Rebecca Hammond, Devon C. Crawford, (unknown), Hong‐Jin Shu, Yukitoshi Izumi, Steven Mennerick, Charles F. Zorumski	215
17	Absence of direct effects on the dopamine D2 receptor by mGluR2/3‐selective receptor agonists LY 354,740 and LY 379,268 2010 ·Synapse ·John R. Zysk, Dan Widzowski, Linda A. Sygowski, (unknown), Nathan Spear, Charles S. Elmore, (unknown), Hongyan Liu, James Doherty, Vijay Chhajlani	11
18	A Selective Allosteric Potentiator of the M₁Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning 2009 ·Journal of Neuroscience ·Jana K. Shirey, Ashley E. Brady, Paulianda J. Jones, Albert A. Davis, Thomas M. Bridges, J. Phillip Kennedy, Satyawan Jadhav, Usha N. Menon, Zixiu Xiang, (unknown), Edward P. Christian, James Doherty, Michael C. Quirk, (unknown), James J. Lah, Allan I. Levey, Michelle M. Nicolle, Craig W. Lindsley, P. Jeffrey Conn	199
19	Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies 2007 ·The Lancet ·Rajesh Krishna, Matt S. Anderson, Arthur Bergman, Bo Jin, (unknown), Josée Côté, Kim Rosko, C.M. Chavez-Eng, Ryan Lutz, Daniel M. Bloomfield, María J. Gutiérrez, James Doherty, (unknown), Jeffrey Chodakewitz, Keith Gottesdiener, John A. Wagner	206
20	Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus 2004 ·The Journal of Physiology ·James Doherty, Sudar Alagarsamy, Kristopher J. Bough, P. Jeffrey Conn, Raymond Dingledine, David D. Mott	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact